Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.
-
Upload
tabitha-morris -
Category
Documents
-
view
218 -
download
6
Transcript of Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.
![Page 1: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/1.jpg)
Drug Discovery & DevelopmentDrug Discovery & Development
PHC 311
LEC. 3Sunday 9/ 11/ 1434H
![Page 2: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/2.jpg)
2
Drug Optimization: Drug Optimization: Strategies in drug designStrategies in drug design I-optimizing drug target I-optimizing drug target
interactionsinteractions
• Drug optimization aims to maximize the interactions of a drug with its target binding site in order to improve activity, selectivity and to minimize side effects.
• Designing a drug that can be synthesized efficiently and cheaply is another priority.
• The aim of drug optimization can be achieved by different strategies or approaches on the lead compound SAR, such as;
![Page 3: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/3.jpg)
General approachGeneral approach
• 1- Molecular disjunction (molecular dissociation, dissection or simplification)
• 2- Molecular conjunctive approach
a- Molecular addition
b- Molecular replication
c- Molecular hybridization
![Page 4: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/4.jpg)
II. Special approachII. Special approach• 1. Ring closure or ring opening• 2. Ring expansion and ring contraction• 3. Homologation and chain branching• 4. Introduction of unsaturation center• 5. Introduction, removal or replacement of bulky
groups• 6. Changes of substitution position• 7. Introduction of chiral center• 8. Conformation restriction (molecular rigidification)• 9. Isosteres and bioisosteres
![Page 5: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/5.jpg)
1. Ring closure or ring 1. Ring closure or ring openingopening
• Diethylstilbesterol may be regarded as a ``ring opening`` modification of estradiol
![Page 6: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/6.jpg)
• Closure of a chain or opening of a ring
![Page 7: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/7.jpg)
• Ring chain transformation has important pharmacokinetic effect as it increase the lipophilicity and decrease the metabolism. So this makes the drug more active in vivo.
![Page 8: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/8.jpg)
2. Ring expansion and ring 2. Ring expansion and ring contractioncontraction
![Page 9: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/9.jpg)
3. Homologation3. Homologation
• A homologous series is a group of compounds that differ by a constant unit, generally a CH2 group.
![Page 10: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/10.jpg)
This phenomenon corresponds to Increased lipophilicity of the molecule to permit penetration into cell membranes until its lowered water solubility becomes problematic in its transport through aqueous media.
In the case of aliphatic amines Micelle formation is a problem which begins at C12. This effectively removes the compound from potential interaction with the receptors.
e.g. 1: Hypnotic activity of alcohols
The maximum effect occurred for 1-hexanol to 1-octanol. The potency declined on chain lengthening until no activity was observed for hexadecanol.
e.g. 2: 4-alkyl substituted resorcinol derivatives
[Antibacterial effect is maximum in case of 4-n-hexyl resorcinol]
![Page 11: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/11.jpg)
Chain branching
• Chain branching decrease the potency.
• The branched side chain is less lipophilic than the straight one.
• The branched chain may interfere with:
- ADME.
- Receptor interaction.
![Page 12: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/12.jpg)
Chain branching
Chain branching lowers the potency of a compound because a branched alkyl chain is less lipophilic than the corresponding straight alkyl chain.
in case of [Homologation] lipophilic relationship is important
The lowered potency may be due to
pharmacokinetics (Absorption, metabolism, excretion,……..etc.)
pharmakodynamics Chain branching may interfere with receptor binding
![Page 13: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/13.jpg)
e.g. 1: Phenyl ethyl amine
NH2 NH2
It is an excellent substrate for monoamine oxidase
(amphetamine) [It is a poor substrate for MAO]
e.g. 2: Primaquine is more potent than its secondary or tertially amine analogues.
N
NH
CH3
NH2
CH3O
Primaquine
[Antimalarial]
![Page 14: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/14.jpg)
e.g. 3: 10-aminoalkylphenothiazines
N
S
CH3
NCH3
CH3
N
S
NCH3
CH3
Promethazine Promazine
Antispasmotic and antihistaminic Antispasmotic and antihistaminic have greatlyreduced and sedative and tranquilizing activitiesare greatly enhanced
N
S
CH3
NCH3
CH3
Trimeprazine
The tranquilizing activity reduced andantipruritic (anti-itch) activity increased
These examples indicate that multiple receptors are involved for 10-aminoalkyl phenothiazines. Branching or homologation can cause the molecule to bind more or less well to the receptors responsible for antispasmodic, antihistaminic, tranquilizing, or antipruritic activities.
![Page 15: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/15.jpg)
4. Introduction of unsaturation 4. Introduction of unsaturation centercenter
• The introduction of an unsaturated group (vinyl, allyl, ethenyl, ethynyl……….etc) in a drug molecule alters its stereochemistry and physicochemical properties and consequently affects its biological activity.
![Page 16: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/16.jpg)
• The increase in hypnotic activity of ethylene (general anaesthetic) than the saturated derivative
![Page 17: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/17.jpg)
5. Introduction, removal or 5. Introduction, removal or replacement of bulky groupsreplacement of bulky groups
• This special process is used mainly to:
• Convert agonist to antagonist or
• Prevent the enzymatic degradation
![Page 18: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/18.jpg)
6. Changes of substitution 6. Changes of substitution positionposition
• The position of certain groups is sometimes essential for given biological for a given biological.
• For example, the three isomers of hydroxybenzoic acid only the o-hydroxy is active, because it can form an intramolecular hydrogen bond and, in this way, it can act as a chelating agent.
![Page 19: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/19.jpg)
![Page 20: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/20.jpg)
7- Introduction of chiral centers
• Receptors are chiral entities and the interactions of many drugs at specific sites chirality of interaction.
• Introduction of chiral centers can alter drastically its pharmacological activity.
• e.g. • the four isomers of choramphenicol, only the D-(-)-
threo-form is active. • L-(-)-ascorbic acid has antiscorbutic activity wherease (+)
ascorbic does not.• R(-)-isomer of epinephrine is more potent on both α-
and β- adrenergic receptors than the S(-)-isomer.
![Page 21: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/21.jpg)
8- Conformation restriction 8- Conformation restriction (molecular rigidification)(molecular rigidification)
• The antimigrain, sumatriptan, undergoes rapid oxidative metabolism of the aminoethyl side chain to the inactive indolacetic acid. Conformmational restriction to give the cyclic piperidine analogue retains the antimigraine activity, but has much longer duration.
![Page 22: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/22.jpg)
• The simple addition of α-methyl group to give ACE inhibitor captopril increased by 10-folds over the des-methyl compound.
![Page 23: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/23.jpg)
Extension of Structure Add extra binding groups to search for nearby binding sites. As a result, we may increase the binding affinity of the drug with binding site By increasing the interactions of the drug with binding site, we could prevent the natural substrate from binding (antagonist)
![Page 24: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/24.jpg)
Increase rigidity and/or structural complexity
O OCH3
N
R
OH
CH3HO
R'
Etorphine: R = CH3, R' = C3H7
Buprenorphine: R =
R' = tert-butyl
CH2
Etorphine -two-carbon bridge -substituent not in morphine -1000x more potent than morphine - used in veterinary medicine to tranquilize large animals
Buprenorphine -10 - 20 times more potent than morphine - Low addictive potential - recently indicated as a therapeutic agent for the treatment of heroin addiction
rigidity increases potency
![Page 25: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/25.jpg)
• Rigidification is used on flexible lead compounds. The aim is to reduce the number of conformations available while retaining the active conformation. Locking Rotatable rings into ring structure or introducing rigid functional groups are common methods of rigidification.
![Page 26: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/26.jpg)
9. Isosteres and Bioisosteres
![Page 27: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/27.jpg)
Why..?
![Page 28: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/28.jpg)
Bioisosterism
![Page 29: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/29.jpg)
• Bioisosterism is a lead modification approach that has been
• shown to be useful to attenuate:
• Toxicity
• Modify the activity of a lead
• May have a significant role in the alteration of
• metabolism of the lead
![Page 30: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/30.jpg)
Parameters affected with isosteric replacement
• Size• Conformation• Polarity• H-Bond formation• Solubility• Hydrophobicity• Reactivity
![Page 31: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/31.jpg)
Classification of isosteres
1- Classical.
2- Non-classical.
![Page 32: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/32.jpg)
Classical Bioisosteres
1. Monovalent atoms and groups (C, N, O, S)2. Divalent atoms and groups (R-O-R, R-NH-R, )3. Trivalent atoms and groups (R-N=R, R-CH=R)4. Tetrasubstituted atoms ( =C=, =N=, =P=,)5. Ring equivalents
Nonclassical Bioisosteres
1. Exchangeable groups2. Rings versus noncyclic structures
The nonclasical bioisosteres do not rigidly fit the steric and electronic rules of the classical bioisosteres
![Page 33: Drug Discovery & Development PHC 311 LEC. 3 Sunday 9/ 11/ 1434H.](https://reader035.fdocuments.us/reader035/viewer/2022070401/56649f1d5503460f94c33a88/html5/thumbnails/33.jpg)
Thank youThank you